The Importance of Risk Assessment as a Foundation of RBQM
CluePoints Appoints Andy Cooper as New Chief Executive Officer
10 reasons people like working at CluePoints
RBQM and ML: Perfect Partners for More Efficient Clinical Trials
Twin Peaks: 10 years of CluePoints and Risk-Based Monitoring
RBQM market leader, CluePoints, marks its tenth anniversary as ICH E6 (R3) looks set to mandate the company’s data-driven approach across all clinical trials
The Inaugural ACDM AI & ML Conference Promises to Move the Dial
Natural Language Processing Improves Risk Signal Documentation in Clinical Trials
Federated Learning & Risk-Based Data Management – The Future of Smart Healthcare
Industry-leading Risk-Based Quality Management event focuses on the maturity of RBQM, its increasing value, and the vision for the future
Find out where we’re headed next.
ICH E6 (R2)
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
ICH E6 (R2)
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.